Skip to main content
SpringerLink
Log in

Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Pasireotide (SOM230) is a multireceptor-targeted somatostatin analog designed to have a broader somatostatin receptor binding profile than other currently available somatostatin analogs. The purpose of this study was to evaluate the absorption, metabolism and excretion of pasireotide in healthy male subjects (N = 4) following a single, subcutaneous (sc), 600 μg dose of [14C]pasireotide.

Methods

Blood, plasma, urine and feces were collected for 240 h post-dose and analyzed for total 14C and metabolite profile by accelerator mass spectrometry (AMS) or high-performance liquid chromatography–AMS. Parent drug levels were analyzed by radioimmunoassay.

Results

[14C]pasireotide was rapidly absorbed, with a mean peak plasma 14C concentration of 16.6 ± 5.28 ngEq/mL at 0.5 h in plasma. The parent drug to total 14C AUC0–24h ratio was 1.08, indicating that little metabolite was present in plasma up to 24 h post-dose. In pooled plasma samples (0–12 h), only unchanged [14C]pasireotide was detected. Unchanged [14C]pasireotide accounted for approximately 84 % of total excretion (feces and urine). Approximately 56 % of the administered radioactive dose was recovered within 240 h, eliminated primarily in feces (48.3 ± 8.16 %) and minimally in urine (7.63 ± 2.03 %). No serious adverse events were reported.

Conclusions

A single dose of [14C]pasireotide 600 μg sc administered to healthy male subjects was rapidly absorbed and excreted in its unchanged form primarily via the hepatic route.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707–716

    Article  PubMed  CAS  Google Scholar 

  2. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho Y-Y, Hu K, Farrall AJ, Melmed S, Biller BM (2010) Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, Phase II trial. J Clin Endocrinol Metab 95:2781–2789

    Article  PubMed  CAS  Google Scholar 

  3. Colao A, Bronstein M, Freda P, Gu F, Shen C-C, Gadelha M, Fleseriu M, Hermosillo Resendiz K, Ruffin M, Chen Y, Sheppard MC (2012) Pasireotide LAR is significantly more effective than octreotide LAR at inducing biochemical control in patients with acromegaly: results of a 12-month randomized, double-blind, multicenter, Phase III study. Endocrine Abstr 29:abst OC1.1

  4. Kvols L, Glusman JE, Hahn EA, Wang E, Öberg K, Anthony L, O’Dorisio TM, de Herder W, Darby CH, Wiedenmann B, The Pasireotide Carcinoid Study Group (2007) The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. J Clin Oncol 25(18S):abst 4558

    Google Scholar 

  5. Novartis Pharma AG. Signifor Summary of Product Characteristics (2012) Available at: http://www.signifor.com/european-product-characteristics.jsp (last Accessed Feb 2013)

  6. Petersenn S, Hu K, Maldonado M, Zhang Y, Lasher J, Bouillaud E, Wang Y, Mann K, Unger N (2012) Tolerability and dose-proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study. Clin Ther 34:677–688

    Article  PubMed  CAS  Google Scholar 

  7. Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Hermosillo Resendiz K, Wang Y, Mann K (2012) Pasireotide (SOM230), a novel multi-receptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers. J Clin Pharmacol 52:1017–1027

    Article  PubMed  CAS  Google Scholar 

  8. Ma P, Wang Y, Van Der Hoek J, Nedelman J, Schran H, Tran L-L, Lamberts SW (2005) Pharmacokinetic–pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 78:69–80

    Article  PubMed  CAS  Google Scholar 

  9. Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M (2012) A first-in-man study to evaluate the safety, tolerability and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther 6:71–79

    Article  PubMed  CAS  Google Scholar 

  10. Horsmans Y, Hu K, Ruffin M, Wang Y, Song D, Bouillaud E, Wang Y, Mazur D, Botha FP, Heuman DM (2012) Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter Phase I study. J Clin Pharmacol 52:552–558

    Article  PubMed  CAS  Google Scholar 

  11. Bazett HC (1920) An analysis of the time-relations of electrocardiograms. Heart 7:353–370

    Google Scholar 

  12. Arjomand A (2010) Accelerator mass spectrometry-enabled studies: current status and future prospects. Bioanalysis 2:519–541

    Article  PubMed  CAS  Google Scholar 

  13. Hamilton RA, Garnett WR, Kline BJ (1981) Determination of mean valproic acid serum level by assay of a single pooled sample. Clin Pharmacol Ther 29:408–413

    Article  PubMed  CAS  Google Scholar 

  14. Roffey SJ, Obach RS, Gedge JI, Smith DA (2007) What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17–43

    Article  PubMed  CAS  Google Scholar 

  15. Beglinger C, Hu K, Wang Y, Bouillaud E, Darstein C, Wang Y, Mohideen P (2012) Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study. Endocrine 42:366–374

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was funded by Novartis Pharma AG. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation. We thank Catherine Henderson DPhil, Mudskipper Bioscience, for medical editorial assistance with this manuscript. We would especially like to thank Yancy Du for helping to develop the HPLC method.

Author information

Authors and Affiliations

  1. Drug Metabolism and Pharmacokinetics, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ, 07936, USA

    T.-H. Lin, K. Hu, J. Flarakos, J. B. Mangold, H. He & Y. Wang

  2. Novartis Pharma AG, Basel, Switzerland

    M. Sharr-McMahon

Authors
  1. T.-H. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Flarakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Sharr-McMahon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. B. Mangold
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. He
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T.-H. Lin.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 13 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, TH., Hu, K., Flarakos, J. et al. Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry. Cancer Chemother Pharmacol 72, 181–188 (2013). https://doi.org/10.1007/s00280-013-2183-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-013-2183-0

Keywords

Search

Navigation